Davy J M, Dorian P, Kantelip J P, Harrison D C, Kates R E
J Pharmacol Exp Ther. 1986 Jun;237(3):907-11.
We have evaluated the electrophysiologic effect of encainide and its three major metabolites, O-demethyl encainide, 3-methoxy-O-demethyl encainide and N-demethyl encainide in an anesthetized dog model. Our results support previous reports that O-demethyl encainide and 3-methoxy-O-demethyl encainide are both more potent than encainide in the depression of conduction. We also have shown that N-demethyl encainide is of about equal potency to encainide. Whereas the major differences between these compounds is primarily one of potency, there are some qualitative differences. Although O-demethyl encainide did not change the ventricular or atrial effective refractory periods significantly, 3-methoxy-O-demethyl encainide and N-demethyl encainide prolonged both. Encainide increased the atrial effective refractory period but did not produce significant changes in the ventricular refractory period. These data support previous suggestions of an important role for these metabolites as modulators of the clinical efficacy of encainide.
我们在麻醉犬模型中评估了恩卡尼及其三种主要代谢产物,即O-去甲基恩卡尼、3-甲氧基-O-去甲基恩卡尼和N-去甲基恩卡尼的电生理效应。我们的结果支持先前的报道,即O-去甲基恩卡尼和3-甲氧基-O-去甲基恩卡尼在抑制传导方面都比恩卡尼更有效。我们还表明,N-去甲基恩卡尼的效力与恩卡尼大致相当。虽然这些化合物之间的主要差异主要在于效力,但也存在一些质的差异。虽然O-去甲基恩卡尼没有显著改变心室或心房的有效不应期,但3-甲氧基-O-去甲基恩卡尼和N-去甲基恩卡尼都延长了这两个不应期。恩卡尼增加了心房有效不应期,但对心室不应期没有产生显著变化。这些数据支持了先前的观点,即这些代谢产物作为恩卡尼临床疗效的调节剂具有重要作用。